Search
Collaboration leads to a new digital pathology tool that allows some doctors to diagnose patient tumors from home.
Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.
This study demonstrates how clonal hematopoiesis (CH)–derived mutations could lead to erroneous reporting and treatment recommendations when tumor-only sequencing is employed. If data about the blood are not part of test results, mutations present in the blood may be misread as mutations in the tumor, which can potentially affect the therapies patients receive. Data presented at the annual meeting of the American Society of Clinical Oncology by Ahmet Zehir, PhD, Director of Clinical Bioinformatics at Memorial Sloan Kettering Cancer Center (MSK) was simultaneously published in JAMA Oncology on June 5.
Read about a CAR T cell therapy that appears effective against light chain (AL) amyloidosis.
The scientific world lost one of its greats this week. Here, we reflect on his influence.
In recognition of Breast Cancer Awareness Month, MSK shared four stories about new developments and advances in breast cancer prevention, research and treatment being conducted by MSK clinicians and researchers.
In an international study led by MSK, researchers reported finding key mutations driving the disease histiocytosis for nearly all of the people included.
Infectious disease expert Mini Kamboj shares what people with cancer should know about COVID-19 and how MSK is keeping our patients and staff safe
Recent advances in epigenetic and targeted therapies owe a lot to the foresight of former MSK President Paul Marks, who believed in the importance of basic research.
Memorial Sloan Kettering “green” committees focus on waste reduction and energy efficiency throughout the institution while donating useful supplies to New York–area nonprofits.